Pasireotide LAR in Severe Polycystic Liver Disease
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will
also assess the efficacy and safety of SOM230 in reducing total liver volume and improving
quality of life.